NIH finds sand fly saliva may be the key to leishmaniasis vaccine

Researchers at the National Institutes of Health reported that a leishmaniasis vaccine based on sand fly saliva has worked well in monkeys. There is no human vaccine for the disease, which is caused by parasites carried by sand flies. They found that monkeys bitten by uninfected sand flies and those injected with a protein from sand fly saliva showed some immunity to the disease. This suggests that the protein could play a part in leishmaniasis infection and could potentially be a component of a vaccine for human leishmaniasis. Abstract | Read more

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.